Hydrogels and cell based therapies in spinal cord injury regeneration by Silva, Rita Catarina Assunção Ribeiro et al.
Review Article
Hydrogels and Cell Based Therapies in
Spinal Cord Injury Regeneration
Rita C. Assunção-Silva,1,2 Eduardo D. Gomes,1,2 Nuno Sousa,1,2
Nuno A. Silva,1,2 and António J. Salgado1,2
1Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho,
Campus de Gualtar, 4710-057 Braga, Portugal
2ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimara˜es, Portugal
Correspondence should be addressed to Anto´nio J. Salgado; asalgado@ecsaude.uminho.pt
Received 8 September 2014; Accepted 14 December 2014
Academic Editor: Pavla Jendelova
Copyright © 2015 Rita C. Assunc¸a˜o-Silva et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Spinal cord injury (SCI) is a central nervous system- (CNS-) related disorder for which there is yet no successful treatment.
Within the past several years, cell-based therapies have been explored for SCI repair, including the use of pluripotent human
stem cells, and a number of adult-derived stem and mature cells such as mesenchymal stem cells, olfactory ensheathing cells,
and Schwann cells. Although promising, cell transplantation is often overturned by the poor cell survival in the treatment
of spinal cord injuries. Alternatively, the therapeutic role of different cells has been used in tissue engineering approaches by
engrafting cells with biomaterials. The latter have the advantages of physically mimicking the CNS tissue, while promoting a more
permissive environment for cell survival, growth, and differentiation. The roles of both cell- and biomaterial-based therapies as
single therapeutic approaches for SCI repair will be discussed in this review.Moreover, as themultifactorial inhibitory environment
of a SCI suggests that combinatorial approaches would be more effective, the importance of using biomaterials as cell carriers will
be herein highlighted, as well as the recent advances and achievements of these promising tools for neural tissue regeneration.
1. Introduction
SCI is a devastating condition that often leads to permanent
functional and neurological deficits in injured individuals.
The limited ability of the CNS to spontaneously regenerate,
mainly due to the establishment of an inhibitory environment
around the lesion site and to the formation of a dense scar
tissue, impairs axonal regeneration and functional recovery
of the spinal cord [1–3].
The annual incidence of SCI has been reported to be
25.5 cases per million [4], at an average age of 31.7 years [5].
Moreover, its prevalence ranges from 236 permillion in India
to 1800 per million in USA [6]. The leading causes of SCI are
motor-vehicle crashes, sports-associated accidents, falls, and
violence-related injuries [7].
The severity of an injury is accurately conveyed by the
five-level (A–E) American Spinal Injury Association (ASIA)
Impairment Scale (AIS). Upon evaluation of the severity of
the damage, the lesion is broadly characterized as complete
or incomplete [8, 9], with distinct clinical implications to the
patients (e.g., paralysis, sensory loss, intractable pain, pres-
sure sores, and urinary/other infections) [5, 8].This generates
tremendous emotional, economic, and social repercussions
for the patients and their families.
The aggressive pathophysiology of SCI contributes to the
extension of this debilitating condition. Amechanical trauma
to the spinal cord triggers an immediate cascade of cellular
and biochemical events that contribute to the progression of
the lesion. Blood vessels disruption and extensive cell death
are some posttraumatic changes that result from the pri-
mary injury [1, 10]. In response to this, a set of secondary
events occur. An inflammatory environment is established
by macrophages, neutrophils, and leukocytes, which are
recruited in order to phagocyte cell debris and prevent further
uncontrolled tissue damage [3, 11, 12]. From days to weeks, a
fluid-filled cyst is formed at the injury site, surrounded by a
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glial scarmainly constituted by reactive astrocytes.These cells
secrete several inhibitory proteins such as chondroitin sulfate
proteoglycans (GSPGs) and axonal growth inhibitors [12, 13],
thus preventing axonal regeneration and remyelination along
the spinal cord. Even though the role of the glial scar is
to stabilize and ultimately protect the damaged spinal cord,
it largely incapacitates spinal cord long-distance functional
regeneration [14], leading to the establishment of a chronic
injury.
Unfortunately, there is still no effective clinical treatment
for SCI, besides some clinical attempts to provide recovery
to patients. As recently reviewed by Silva et al. [14], the most
usual procedures rely on surgical techniques, including sur-
gical decompression and further stabilization of the spine, as
well as on pharmacological interventions. Several pharmaco-
logical agents have been studied in this context [15], high dose
methylprednisolone (MP) administration being an option
for the treatment of acute SCI. However, its efficacy is quite
limited due to severe side effects [14, 16].Therefore it is recom-
mended to be given to patients only with the knowledge that
evidence suggesting harmful side effects is more consistent
than any possible clinical benefits [17].
In recent years, tissue engineering and regenerative
medicine based approaches have been proposed as alterna-
tives for SCI repair/regeneration. For the past decades, cell-
based therapies have been highlighted for SCI regeneration
[18], as well as engineering approaches using biomaterials.
Nowadays, the combination of biomaterials with cell trans-
plantation is also beingwidely explored in the scope of SCI. In
this context, biomaterials are expected to stabilize the lesion
site, while directly delivering the cells into it, and provide an
adequate environment for the regeneration of the injured tis-
sues. Several cell types and biomaterials have been suggested
for the development of promising regenerative strategies for
SCI. Therefore, the aim of this review is to address the recent
progress that has beenmade in both approaches. A discussion
on the potential of these therapies for SCI regeneration
will be the starting point, after which the contributions of
biomaterials for the development of more efficient cell-based
therapies will be also discussed.
2. Cell-Based Therapies for SCI Repair
Aiming at developing successful therapies for SCI treatment,
the transplantation of certain cell populations into damaged
areas has been one of the most used regenerative approaches
over the years. Among the alternatives, stem-cell based trans-
plantation has been gathering attention for the past 15 years
[19–23]. Most of the times stem cells are used because of their
differentiation potential [24–26]; however they have been
also shown to be able to provide a large repertoire of sig-
nalingmolecules, including anti-inflammatory cytokines and
growth factors. These may modulate the inhibitory environ-
ment of SCI while increasing the trophic support to resident
cells [27–32]. So far, stem cells from different origins have
been tested for their ability to stimulate nerve regeneration
and restore the neuronal circuitry when integrated in the
injured site [14, 33].
2.1. Embryonic Stem Cells. One of the cell populations pro-
posed for SCI regeneration is embryonic stem cells (ESCs)
[34], which are known to differentiate into all fetal cell
lineages [24], thus being considered as pluripotent.
The ability of ESCs to differentiate into neural and glial
cells in in vitro culture systems has been extensively explored
using different strategies. Retinoic acid (RA) and embryoid
body- (EB-) based protocols have been used to induce neural
differentiation of ESCs in culture, resulting in the activation
of a complex system of neuronal gene expression provided
by neuronal like cells [35] and in the production of oligoden-
drocytes, capable of producing myelin for the myelination of
neurons in culture [19]. Another approach, consisting in the
use of specific factors in mouse ESCs culture, was found to
efficiently direct cell differentiation into dopaminergic and
serotonergic neurons [36, 37]. The use of cell culture media
specifically defined for ESCs commitment to the neural fate
is also an alternative method [38]. Of particular interest is the
possibility to genetically modify the ESCs, in order to obtain
neuronal precursors-enriched cultures [38, 39].
The suitability of ESCs-based approaches for SCI treat-
ment has also been investigated in a number of spinal cord
injury models. Keirstead et al. [34] transplanted neural stem
cells (NSCs) obtained frommouse ESCs into a rat spinal cord,
after an induced thoracic SCI. Most transplanted cells sur-
vived, migrated away from the injury site, and were shown to
preferentially differentiate into oligodendrocytes and astro-
cytes [34]. Still, induced ESC-derived oligodendrocyte pro-
genitor cells transplanted into demyelinated spinal cordswere
found to contribute to the remyelination of host axons. In the
same report, the improvement of animalsmotor performance
upon transplantation was also described [19]. Finally, ESC
clinical applications in SCI patients started through a Phase
I clinical trial provided by Geron’s company in 2011. A
cohort of patients with complete subacute thoracic SCI was
transplanted with predifferentiated oligodendrocyte precur-
sor cells derived from human ESCs for safety studies. Unfor-
tunately, Geron’s program was aborted later in that year [40].
Nevertheless, to date no safety issues were reported in five
patients submitted to ESCs transplants.
2.2. Induced Pluripotent Stem Cells. Recently, another type of
pluripotent stem cells, known as induced pluripotent stem
cells (iPS cells or iPSCs), emerged as a possible alternative
to obtain stem cells directly from adult tissues for autolo-
gous transplantation. The iPSCs technology resulted from a
pioneer work developed by Yamanaka’s lab in Japan in 2006,
which showed that the introduction of four transcription fac-
tors reverted the phenotype of differentiated adult cells into
pluripotent stem cells [41]. iPSCs are often compared to ESCs,
as they share similar characteristics, such as pluripotency,
self-renewal capacity, and gene expression [42, 43].Moreover,
the potential to acquire abnormal karyotypes and genetic
amplification associated with teratoma formation is also a
common feature between the two cell types [42, 43].However,
iPSCs differentiation into neural lineages occurs at a lower
frequency than for ESCs [44].
The fact that iPSCs can be derived directly from adult
tissues offers an unlimited supply of autologous cells, which
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could be used to generate transplants without the risk of
immune rejection. However, safety issues such as those
related to tumor formation should be determined prior to
their clinical application. Therefore, it is crucial to carefully
test iPSCs for tumorigenicity [42, 45]. In line with this, Zhao
et al. [21] presented a study concerning the immunogenicity
of iPS cells in vivo. A teratoma formation assay was used to
show that iPSCs efficiently formed teratomas in mice, with a
strong immune-rejection of the cells [21]. Later in 2013, Araki
et al. [46] attempted to reproduce the conclusions obtained
by Zhao and colleagues using a different procedure. By trans-
planting cells from a chimera obtained from iPSCs clones
and a mouse embryo into mice, little or no immunogenic
response was observed [46].
Although these recent reports have emphasized the
pitfalls of iPSCs technology, others supporting the efficacy
of iPSCs as cellular systems for SCI treatment are also
accumulating. For example, human iPSC-derived neuro-
spheres (hiPSC-NSs) survived, migrated, and differentiated
into the three major neural lineages after transplantation
into a nonobese diabetic-severe combined immunodeficient
(NOD-SCID) SCI model mice. The formation of synapses
between grafted cells and host mouse neurons was promoted,
as well as the expression of neurotrophic factors, angiogene-
sis, axonal regrowth, and myelination in the injured area. As
a result, there was an improvement of the functional activity
of the hiPSC-NSs-grafted mice, with no tumor formation
[47]. More recently, a preclinical study investigated the
therapeutic potential of transplanting preevaluated neural
stem/progenitor cells (NS/PCs) clones derived from murine
and human iPSCs (iPSC-NS/PCs) into a nonhuman primate
model of contusive SCI [26]. Similarly to previous studies,
the grafted cells were found to survive and differentiate into
neurons, astrocytes, and oligodendrocytes, without evidence
of tumor formation. In addition, there was an enhancement
in axonal sparing/regrowth and angiogenesis at the lesion site
and the prevention of the lesion epicenter demyelination. At
the end of the treatment, a functional recovery of the animal
after SCI was observed [26]. Nevertheless, more preclinical
studies have yet to be performed, in order to investigate the
true potential and safety of iPSCs, before moving to a clinical
setting.
2.3. Neural Stem Cells. Another cell population with a possi-
ble interest for SCI research is adult multipotent NSCs [27],
which are particularly appealing due to their CNS origin.
These cells have been shown to generate the threemain neural
cell lineages of themammalianCNS in culture [25].Thus they
can hypothetically allow the replacement of spinal neurons
lost after injury anddifferentiate towards astrocytes, to restore
the nonneuronal milieu of the preinjured spinal cord, or
towards oligodendroglia, to allow remyelination [27]. In fact,
previous studies have confirmed this theory.The engraftment
of NSCs into a SCI model of contused adult rat spinal cord
resulted in the production of neurons that migrated long
distances rostrally and caudally, with observed functional
improvement [48]. In a cervical contusion-induced SCI in
primates, in vitro-expanded human neural stem progenitor
cells (NSPCs) were grafted nine days after injury and were
shown to survive and differentiate into the neural lineages. In
addition, there was a decrease in the injury cavities extent, as
well as a significant increase of the spontaneous motor activ-
ity of the transplanted animals [20]. Furthermore, demyeli-
nated axons in NOD-SCID mice with traumatic SCI were
remyelinated after transplantation of humanCNS cells grown
in aggregates (hCNS-SCns). These cells also differentiated
into neurons that exhibited the ability of synapse formation
with host neurons [49]. More recently, it has been reported
that transplantation of fetal NSCs into complete rat spinal
cord transection sites led to the formation of ectopic colonies
twomonths after cell engraftment.These colonies were found
to disseminate in widespread areas of the host CNS and
continuously proliferate in several neural-cell lineage types
[23].
In other studies, the NSCs capacity to promote axonal
regeneration was related with the secretion of neurotrophic
factors [27]. First in vitro, and then in vivo, intrinsic growth
factor production by NSCs was found to support extensive
growth of host axons, which are known to be sensitive to these
factors [27]. Furthermore, it was observed that the genetic
modification of NSCs alters the overall axonal responses.
For instance, the induction of neurotrophin-3 (NT-3) pro-
duction by NSCs has significantly expanded the growth and
penetration of host axons along the injury site [27, 50].
The experimental ground work regarding NSCs as
cellular-based therapy has shown promise in repairing dam-
aged cells and tissues after SCI and ultimately led to the
attempt of applying this therapy to humans. In line with
this, Stem Cells Inc. Company (Switzerland) established the
world’s first clinical trial in spinal cord injured humans using
these cells [51]. In 2011, the company initiated a Phase I/II
clinical trial designed to assess both safety and preliminary
efficacy of a single transplantation of purified fetal human
neural stem cells (HuCNS-SC), as a treatment for chronic
thoracic SCI, for both complete and incomplete injuries. The
study enrolled seven patients with complete injuries (AIS
A) and five patients with incomplete injuries (AIS B). The
cells were directly injected into their spinal cords, and they
were temporarily immunosuppressed. Clinical updates were
reported on a total of eight of the 12 patients enrolled in
the clinical trial. With regard to AIS A patients, there was
significant posttransplant gain in sensory function in four
patients up to date. Concerning AIS B subjects, two of three
patients had significant gain in sensory perception, the third
remaining unaltered [51].
2.4. Mesenchymal Stem Cells. In the last decade, mesenchy-
mal stem cells [52] (MSCs) have also been in the forefront
of cell-based strategies for SCI regeneration. These cells were
first described to be present in the bone marrow by Frieden-
stein and colleagues [53]. They were mainly characterized
by the ability to adhere to plastic in culture, to develop into
fibroblastic colony forming cells (CFU-F), and to differentiate
into osteoblasts, adipocytes, and chondroblasts in vitro [53–
55].
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Figure 1: Application of MSCs as a treatment for SCI. The MSCs secretome is believed to be a key player on the promotion of neurore-
generation and neuroprotection, as well as the modulation of the inflammatory response.
Availability is one of the advantages of MSCs comparing
with other cells, as they can be found in several tissues [56–
59]. In addition,MSCs isolation can be easily performed [60],
without rising any ethical or political issues.
The efficacy of MSCs as therapeutic agents for CNS
has been related to different theories, starting from their
engraftment efficiency when injected into the body [54] to
their differentiation into neural phenotypes.The latter was in
fact studied both in vitro, where bone marrow MSCs (BM-
MSCs) were found to putatively differentiate into neuron-
like cells and glial cells [52], and in vivo, where the authors
found BM-MSCs were able to migrate across the blood-
brain barrier (BBB1), repopulate the CNS, and differentiate
into microglia-like cells [61]. Despite these findings, this is
still a controversial topic. Indeed, it is more likely that the
MSCs potential is associated with their trophic activity [28,
29, 55, 62, 63]. MSCs secrete a set of bioactive molecules
and/or microvesicles—their secretome—which is believed to
mediate both paracrine and autocrine MSCs activities [29,
62]. In response to injury, the secretome may support the
repair and regeneration of damaged tissues by suppressing
local immune response [64], enhancing angiogenesis and
inhibiting scarring and cell apoptosis [65] (Figure 1).
These outcomes support the multifactorial roles of MSCs
transplantation on CNS tissues and cells. Further details on
this topic can be found elsewhere [28, 30].
In the context of SCI treatment, different strategies have
been considered. While some are solely focused on the trans-
plantation of MSCs in the injury site, others are more inter-
ested in the administration of their secretome in the same
area in order to support the survival and proliferation of the
remaining cells. Regarding the transplantation ofMSCs, both
intravenous [66–68] and subcutaneous [68] injections have
been proposed, as well as a direct injection in the injury site
[69].MSCs transplantation by cellmobilizationwith granulo-
cyte colony-stimulating factor (G-CSF) [68, 70] or intrathecal
catheter delivery [67, 71] was also explored. In all of these
studies the authors reported functional recovery after SCI.On
the other hand, studies regarding the use of MSCs secretome
have also shown promising results. For instance, the condi-
tioned medium (CM) of BM-MSCs promoted the survival
and neurite outgrowth of hippocampal neurons in vitro [72].
In another study, both adipose stem cells (ASCs) and human
umbilical cord perivascular cells (HUCPVCs) CMs were
shown to increase hippocampal neurons survival and meta-
bolic activity [73].More recently, the secretome ofHUCPVCs
was also found to increase cell viability, proliferation, and
neuronal cell densities in both cortical and cerebellar neu-
ronal cultures [74]. Other in vitro and in vivo studies showed
similar results [75–77].
MSCs application into SCI clinical trials has been widely
studied and throughout themMSCs biosafety has been quite
explored. In a Phase I/II clinical study, autologous BM-MSC
transplantation as well as bone marrow stimulation with
macrophage colony stimulating factor (GM-CSF) was used
to treat complete SCI [78]. Likewise, the transplantation of ex
vivo expanded autologousMSCswas also used in pilot clinical
studies [79, 80]. Currently, autologous BM-MSCs implanta-
tion in an acute and chronic SCI at cervical and thoracic level
is being used in a Phase I/II clinical trial [67]. Even though
90%of patientswith acute cervical injuries showed significant
improvement, only mild improvement was found in chronic
patients. Nevertheless, a larger group of patients is needed to
evaluate the efficacy of this therapy. Mononuclear BM cells
transplantation for SCI treatment can also be used in alterna-
tive to BM-MSCs, as it was shown to have a similar efficiency
in vivo [81]. In fact, the clinical safety and primary efficacy
data of autologous BM-derived mononuclear cells for SCI
were already studied in a Phase I/II clinical trial involving
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traumatic paraplegia (𝑛 = 215), traumatic quadriplegia (𝑛 =
49), and nontraumatic spinal cord myelopathy (𝑛 = 33) [82].
In this study, the cells were delivered through a lumbar punc-
ture and a 3-month periodic follow-up study was designed to
analyze neurologic andmotor improvements, as well as safety
parameters such as the therapeutic time window, CD34+
cell count, and influence of sex and age. At the end of the
study, neurological status improvement was observed in one-
third of SCI patients. Moreover, the outcome of the therapy
was only influenced by: (1) the time elapsed between injury
and treatment; and (2) the number of CD34+ cells that was
injected [82].
According to all of these findings, MSCs may be equally
powerful tools for SCI regeneration-based strategies.
2.5. Glial Cells. The possible role of other mature cells on
the SCI regenerative process has attracted the attention of
investigators in the field. For that purpose, glial cells including
olfactory ensheathing cells (OECs) and Schwann cells (SCs)
have been explored over the past decade.
2.5.1. Olfactory Ensheathing Cells. OECs are glial cells that
ensheath olfactory axons, within both the PNS and CNS
portions of the primary olfactory pathway [83], and that are
responsible for the successful regeneration of olfactory axons
throughout the life of adult mammals [84]. These cells have a
highly malleable phenotype, most likely due to coexpressing
phenotypic features of astrocytes and SCs [85]. According to
this theory, it is believed they can either switch from one type
to another depending on their needs, or combine the roles of
both when transplanted into an injury [83, 85].
At a glance, OECs might seem a curious choice for cell
transplantation. The mammalian olfactory system is unique
in supporting axonal outgrowth from its peripheral neuronal
cell bodies in the olfactory epithelium into the CNS olfactory
bulb, throughout life [86]. Furthermore, the expression of
SCs-specific phenotypic features by OECs led to the hypoth-
esis that these cells facilitate the growth and the myelination
of axons within the CNS of adult mammals. The initial study
that inspired OECs transplantation into CNS was performed
by Ramon-Cueto and Nieto-Sampedro [87]. OECs were
grafted into the dorsal-root entry zone of the postdevel-
opmental CNS. The grafted cells were able to promote the
regrowth of transected dorsal roots, which was interesting
since this is a region where normally dorsal root regeneration
does not occur [87]. After these findings, numerous studies
have demonstrated the effectiveness of OECs in supporting
nonolfactory CNS axons growth and remyelination. Evi-
dences showing the ability of OECs to myelinate dorsal root
ganglion (DRG) neurons in vitro were firstly provided by
Doucette and Devon in an in vitro coculture system [83, 88].
The myelination of DRG neurites by these glial cells was
clearly observed and resembled the process by which SCs
myelinate peripheral axons [83]. Subsequently, OECs were
found to be able to remyelinate axons in vivo by Franklin
et al. [89] and Imaizumi et al. [90]. In these studies, OECs
were transplanted into an x-irradiated demyelinated area of
the adult rat spinal cord.These cells remyelinated the existent
axons after transplantation [89], which were found near
and remote from the cell injection site, indicating extensive
migration of OECs throughout the lesion [90]. Moreover, the
remyelinated axons displayed improved conduction velocity
and frequency-response properties, with action potentials
being conducted at a greater distance into the lesion [90].
Although the effectiveness of OECs in supporting CNS
regeneration was extensively studied and clearly showed,
some negative reports have been presented. In a first line of
evidence against this idea, Plant et al. [91] showed that OECs
from adult rats did not myelinate DRG neurites. OECs failed
to exhibit the so-described “Schwann-like” pattern of myeli-
nation. In contrast, “flat meandering processes” of OECs
were observed encircling the DRG neurites [91]. Later on,
the reparative ability of these cells in a contusion injury of
the spinal cord was evaluated. After transplantation, OECs
exerted a poor effect over axonal outgrowth andmyelination,
as well as functional hindlimb recovery of the animals [92].
As a conclusion, it is widely considered that OECs can
create a permissive environment for axonal regeneration in
the hostile environment of a SCI. While this is associated, by
several authors, with the glial cell ability to support axonal
growth and remyelination, others attribute this phenomenon
to their secretome. In fact, OECs were found to secrete
nerve growth factor (NGF), brain-derived neurotrophic fac-
tor (BDNF), neuregulins [31], and glial cell line-derived
neurotrophic factor (GDNF) [32].
Regarding OECs transplantation into human SCI, some
clinical trials have already been performed.The feasibility and
safety of autologous OECs transplantation into patients with
complete thoracic injuries was tested in a Phase I/II clinical
trial [93, 94]. One year [93] and three years [94] after cell
implantation into the damaged area, no complications were
observed regarding the safety of the procedure. No spinal
cord cyst or tumor formation was reported, neither neuro-
pathic pain nor deterioration in neurological status. Also,
there were no significant functional changes in any patients.
In contrast, a Phase I/II pilot clinical study performed by
Lima et al. [95] showed that the transplantation of olfactory
mucosa autografts in patients with severe chronic SCI had
promoted motor improvements in 11 patients (out of 20).
Although some adverse events were reported in 5 of the
patients, the growth of nonneoplastic tissue in the lesion site
of all of them was observed.
2.5.2. Schwann Cells. Over the years, it has been considered
that SCs might be useful tools as cell therapies for CNS
injuries such as SCI. This idea is based on the possibility that
SCs might allow damaged CNS axons to regrow and remyeli-
nate in the same way as it occurs in the PNS [96]. However, it
has been postulated that the suitability of SCs could be dimin-
ished in the presence of astrocytes [97]. Recalling that this
cell type is present in areas of SCI, such hypothesis would be
imposing the idea that SCs transplantation within astrocyte-
rich environment would unable these cells to integrate exten-
sively within it [98]. Despite the evidences supporting this
theory, there are several studies indicating that SCs are able to
promote regeneration, while myelinating axons in SCI sites,
thus being a good candidate to mediate the repair of such
lesion. To corroborate this, experiments with autologous SCs
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transplantation were performed in thoracic injuries of cat
spinal cords. In twelve animals (out of 25), all surviving axons
in the dorsal column were remyelinated by the transplanted
cells at injury level [99].There was also a peripheral myelina-
tion of the dorsolateral tracts in six cases [99]. Furthermore,
in a transected nude rat spinal cord, grafts of human SCs
promoted axonal regeneration and myelination of several
neuronal populations in the lesion site. Some regenerative
growth also occurred beyond the graft, accompanied by a
modest improvement in function [100]. More recently, adult
SCs were found to sustain neuronal survival and promote
axonal regeneration and hindlimb locomotor performance
in a moderately contused adult rat thoracic spinal cord [92].
Thereafter, autologous transplantation of mitogen-expanded
SCs in a model of acute demyelination of a monkey spinal
cord resulted in functional and anatomical repair of the
lesion, aswell as in repair of large areas of demyelination [101].
Another interesting fact was that genetic-modified SCs
that overexpress NGF [102] or BDNF [103] robustly increased
axonal growth and remyelination after transplantation into
SCI adult rats [102, 103]. Interestingly, grafted SCs exhibited
a phenotypic and temporal course of differentiation that
matched patterns normally observed after peripheral nerve
injury [102].
So far, the evidences show the potential of SCs as cell
transplants to integrate into SCI. As a result, their clinical
translation has been described in a number of interesting
reports. For instance, Saberi’s group focused on the autolo-
gous transplantation of SCs into patients with chronic spinal
cord injuries.The cells were injected directly into the lesioned
area [104] or by intramedullary delivery [105]. In both studies,
no adverse effects were observed one year [104] and two years
[105] after cell transplantation, even though beneficial effects
were not observed. In general, the procedures conducted
were found to be safe. More recently, the Miami Project to
Cure Paralysis performed the first-ever FDA approved SCs
transplantation in a patient with complete thoracic SCI. The
aim of this Phase I clinical trial is to evaluate the safety and
feasibility of transplanting the patient’s own SCs. Therefore,
the patient received his own SCs about four weeks after injury
and there have been no adverse consequences, so far. The
project is nowmoving forward with this Phase I clinical trial,
enrolling a total of eight participants with acute thoracic SCI
[106].
Regardless of the advances in cell therapy for SCI treat-
ment revealing to be promising, this approach is usually
applied acutely and subacutely. However, cell transplantation
for SCI often fails to yield functional recovery [13].When cells
are simply directly delivered into the injury site at this phase,
an elevated percentage does not survive to the profound
hypoxic and ischemic environment. Therefore, alternatives
are needed in order to efficiently deliver cells and cell based
therapies within SCI sites.
3. Biomaterials as a Tissue Engineering
Approach for SCI Repair
The limited regenerative capacity of the CNS is well known.
Besides the inhibitory environment that is created after
damage, as it occurs in SCI, there is a lack of a physical matrix
where neurons and endogenous repairing cells can adhere.
These are two of the main reasons supporting the use of bio-
materials in SCI-related research. In this sense, biomaterials
science and tissue engineering approaches have been in the
forefront of new strategies to approach SCI treatment. Among
the biomaterials available, hydrogels appear as an excellent
option, mainly due to their physical properties, which can
closely mimic the soft tissues environment and the architec-
ture of the CNS. Also, their chemical composition can be
adapted to integrate extracellular matrix (ECM)molecules as
well as other adhesion proteins, aiming at efficiently support
and guide axonal regeneration. Interestingly, the develop-
ment of hybrid matrices is also an approach used for SCI
repair, since one can benefit from the properties of different
materials to promote SCI recovery [107–109].
Taking this into account, this section will focusmainly on
biomaterials application in a SCI context, particularly the use
of hydrogel-based strategies.
3.1. Hydrogel-Based Biomaterials for SCI Treatment. For clin-
ical applications, the design of a biomaterial must satisfy
some essential criteria, such as biocompatibility, so it does
not trigger any immune response from the host; specific tai-
lored mechanical and physicochemical properties that allow
both spinal cord stabilization and cell attachment and growth;
porosity and permeability for the diffusion of ions, nutrients,
and waste products; and biodegradability, so the biomaterial
degrades as new tissue grows, thus mimicking the natural
mechanisms of breakdown and synthesis of ECM in the
natural tissues [14, 110, 111]. Among the variety of available
materials for tissue engineering, hydrogels are particularly
appealing for neural tissue repair, because their properties
match all these requirements. Actually, hydrogels have physi-
cal properties that allow them to be injected into the body in
a noninvasive manner. Moreover, they can be administered
in a localized manner and are also able to fill the defects
caused by injury [14, 112, 113]. Therefore, they act as depots
for a sustained release of cells andmolecules at the injury site.
As cell delivery agents, hydrogels also improve cell survival
and integration [114]. Structurally, they are very similar to
macromolecular-based components in the body and are con-
sidered biocompatible, namely, when derived from natural
polymers [115]. Also, their high water content has the advan-
tage over other matrices of better mimicking the aqueous
environment of the ECM [116].
A number of hydrogels have been developed for SCI
repair, including natural-based hydrogels such as algin-
ate [108, 117, 118], agarose [119–121], collagen [122–124],
fibronectin [125, 126], fibrin [127, 128], matrigel [122, 129],
and gellan-gum [109, 130, 131], as well as synthetic biode-
gradable-based hydrogels, namely, poly(lactic acid) (PLA)
[132, 133], poly(lactic-co-glycolic acid) (PLGA) [134, 135],
poly(ethylene glycol) (PEG) [136, 137], and the nonbiode-
gradablemethacrylate-based hydrogels, including the poly(2-
hydroxyethyl methacrylate) (pHEMA) [107, 122, 138] and
poly(hydroxypropyl methacrylate) (pHPMA) [139–141].
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3.2. Natural-Based Hydrogels. An important aspect to be
considered when developing a hydrogel is its integration and
interactionwith the host tissue.Therefore,many of the hydro-
gel formulations used in biomedical applications include
natural polymers or molecules present in living tissues.
For neural tissue repair, natural-based hydrogels are sub-
stances that normally appear in natural ECM or have certain
properties that are recognized by cells, facilitating their inte-
grationwithin the host [142, 143], thus being preferred for SCI
repair. Moreover, they exhibit similar properties of the soft
tissues they are replacing [143]. However, since these mate-
rials derive from natural sources, they may elicit immune
reactions from the host where they will be implanted and
heterogeneity between batches may also be observed [144].
Among the above referred natural hydrogels, we will
herein focus on agarose, alginate, collagen, fibrin, chitosan,
and gellan-gum.
3.2.1. Agarose. Agarose is a polysaccharide of D-galactose
and 3,6-anhydro-L-galactopyranose that has tissue-like
mechanical properties and has been widely used for drug
delivery strategies due to its porous nature [120]. In addition,
agarose gels have also the potential to be applied as nonviral
gene delivery systems as they have been shown to provide
a slow release of bioactive, compacted DNA [145]. Being
derived from cell walls of red algae, agarose is a biocompatible
component, which enables it to be used in tissue engineering
approaches.
One aspect of agarose gels that makes them particularly
interesting for CNS-related diseases is their ability to poly-
merize in situ, so they can fill different types of neurological
defects, adapting to the shape of the lesion [120]. Moreover,
this type of hydrogel has already shown the capacity of
supporting neurite extension in vivo [120].
In two different rat models of SCI (contusion and dorsal-
over hemisection), agarose gels were used as reservoirs for
MP-loaded nanoparticles [146, 147]. This kind of construct
allowed for a local and gradual release of the drug, with
improved effects on reduction of the lesion volume and
expression of proinflammatory proteins, when compared to
systemic MP delivery [146, 147]. Agarose-based hydrogel has
also been used for harboring lipid microtubes loaded with
different drugs, namely, chondroitinase ABC (chABC) [148].
This system facilitates a local sustained release of chABC,
consequently reducing the deposition of chondroitin sul-
fate proteoglycans (CSPGs, a major class of axonal growth
inhibitors) and obviating the use ofmore invasive, continuous
drug delivery systems (such as pumps or catheters) [148]. In
an identical approach, agarose gels were coupled with lipid
microtubes loaded with constitutively active Rho GTPases
(Cdc42 and Rac1), which reduced CSPGs deposition and
reactive astrocytes, promoting axonal growth in CSPG-rich
regions [149]. More recently, a bioengineered agarose scaffold
proved to support motor axon regeneration after a complete
transection SCI model [150]. Moreover, the fabrication of
channels within the gel allowed a more linear and organized
axonal growth [121, 150]. In another study, agarose gels were
modified to become photolabile and then, after the exposure
to a focused laser, physical and chemical channels were cre-
ated, by simultaneously immobilizing a fibronectin peptide of
glycine-arginine-glycine-aspartic acid-serine (GRGDS) into
their structure. These channels were found to provide guid-
ance in cell migration and neurite outgrowth [151].
3.2.2. Alginate. Another polysaccharide derived from cell
walls of algae (brown algae) is alginate, which is able to absorb
200–300 times its own weight in water [152]. Composed
of repeating units of (1–4)-linked 𝛽-D-mannuronate and 𝛼-
L-guluronate [153], it has been used as a substrate for cell
encapsulation, cell transplantation, and tissue engineering
applications [108, 154, 155]. The gelation of this hydrogel
occurs upon interactions between the carboxylic acid moi-
eties and different counterions, like calcium [156]. However,
the gelation procedure can be also based on the existence of a
physical network, stabilized by intermolecular hydrophobic
interactions between alkyl chains linked to the alginate
backbone [154].
Alginate gels with hydrophobic domains provide a good
retention of proteins that could be released upon the dissoci-
ation of the hydrophobic junctions [154].
In in vivomodels, alginate hydrogels were also applied for
the delivery of growth factors, including vascular endothelial
growth factor (VEGF). After the application of a mechanical
stress to the hydrogel, increased amounts of VEGF were
released from the gels, leading to enhanced neovascular-
ization processes within alginate hydrogels [157]. In acute
cervical spinal cord lesions of adult rats, alginate-based
highly anisotropic capillary hydrogels induced directed axon
regeneration across the implanted artificial scaffold [108].
Sincemammals do not possess enzymes capable of degrading
high molecular polymers of alginate, the addition of PLGA
microspheres loaded with alginate lyases to the gel can pro-
vide a tunable and controlled enzymatic degradation of this
natural hydrogel [158]. In amore recent study, alginate hydro-
gels were used as deposits of GDNF (either free or inside
microspheres) and injected into an injury of a hemisection
model of SCI in rats. After either six weeks or three months,
more neurofilaments were observed in the lesion of the ani-
mals treated with free GDNF loaded hydrogels, as compared
to microspheres-GDNF-treated or untreated controls. In
addition, the same group of animals presented less glial fibril-
lary acidic protein (GFAP) staining andmore endothelial and
nerve fiber infiltration at the lesion site. Superior functional
recovery was also observed in free GDNF-treated rats, as
assessed by gait analysis [118].
3.2.3. Collagen. Collagen is one of the major proteins found
in the ECM of different tissues in mammals [159]. It is mainly
synthesized by fibroblasts and there are up to 29 different
collagen types, the type I being the most common [159]. In
addition, gel formation can be induced just by changing the
pH of a collagen solution [143]. Collagen-derived materials
are therefore highly biocompatible, but also biodegradable
and noncytotoxic, having the ability to support cellular
growth [159]. In this sense, collagen has been widely used
in clinics, in different applications such as recovery of tissue
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defects, burns, wound dressings, and nerve regeneration
[160]. As major drawbacks, collagen mechanical behavior in
vivomay be variable and sometimes it may elicit an antigenic
response, namely, if cross-species transplantation is used
[161]. Other concerns include variability in the enzymatic
degradation rate, when compared with hydrolytic degrada-
tion, and presence of trace impurities [159].
In what concerns collagen application to SCI, Jimenez
Hamann et al. [162] developed a concentrated collagen
solution for the localized delivery of different growth factors.
Collagen with epidermal growth factor (EGF) and fibroblast
growth factor 2 (FGF-2) was injected into the subarachnoid
space of injured Sprague-Dawley rats. This resulted in less
cavitation at the lesion epicenter (and also in other caudal
areas), associated with more white matter sparing, as com-
pared to nontreated animals [162]. In another study, collagen
filaments were grafted parallel to the spinal cord axis of
SCI rats, working as a bridge to foster neuronal regeneration.
After four weeks, regenerated axons crossed the proximal and
distal spinal cord-implant interfaces. Following twelve weeks,
rats presented improved locomotor behavior and somatosen-
sory evoked potentials (SSEP) were observed [123]. More
recently, multichannel collagen conduits were used as reser-
voirs for neurotrophin-3 (NT-3) gene delivery in SCI rats.
One month after injury, an aligned axonal regeneration was
observed, and a higher number of regenerating axons were
found in the conduits delivering NT-3 [124]. The association
of collagen scaffolds to basic FGF also induced significant
improvements in motor behavior of SCI rats and allowed
guided growth of fibers through the implants [163].
3.2.4. Fibrin. Hydrogels based on fibrin have also been
extensively explored for SCI treatment. Fibrin is a fibrous
protein that is involved in blood clotting. It is produced
during the coagulation cascade, when fibrinogen is cleaved by
thrombin, giving origin to fibrinmonomers.Thereafter, these
monomers spontaneously polymerize and create a three-
dimensional (3D) matrix [164]. One important aspect of
fibrin is the possibility to control their gelation process by
varying the concentration of thrombin used. This feature
offers the possibility of maintaining fibrin at a liquid state
during injection, while forming a solid scaffold in vivo [165].
However, there are also some disadvantages. Fibrin gels from
mammalian origin tend to degrade rapidly [166, 167] andmay
be easily contaminated by blood-derived pathogens or prion
proteins [168]. In addition, some reports show that autolo-
gous mammalian fibrinogen inhibits neurite outgrowth [169]
and activates resident astrocyte scar formation [170].
Regarding the use of fibrin in SCI applications, Iwaya
et al. showed in 1999 that it was an effective intermediate
for intraspinal delivery of neurotrophic factors [171]. In the
same line of thought, Taylor et al. managed to deliver NT-
3 within fibrin scaffolds to SCI rats. Nine days after injury,
this treatment elicited a more robust neuronal fiber growth
into the lesion, in comparison to control groups. A dramatic
reduction of glial scar formationwas also observed. However,
no differences in motor recovery were found between groups
[128]. More recently, with the purpose of avoiding some of
the mammalian fibrin side effects, Sharp et al. tested salmon-
derived fibrin as an injectable scaffold for SCI [165]. Salmon
fibrin-treated animals showed greater recovery of locomotor
and bladder function and even more serotonergic innerva-
tion caudal to the lesion, as compared to animals treated with
human fibrin or untreated controls. Furthermore, no effects
were observed on glial scar formation or lesion volume [165].
Additionally, in 2010 King et al. used injectable forms of fibrin
mixed with fibronectin (FN/FB) to support axonal ingrowth
after SCI [126]. One week after injury, the mixture showed
good integration with the host spinal cord and supported
some degree of axonal growth. After four weeks, axonal
growth in FN/FB implants was the greatest compared to other
implants tested [126].
3.2.5. Chitosan. The linear polysaccharide chitosan is also a
good alternative as a regenerative biomaterial-based strategy
for SCI. This polysaccharide is composed of randomly dis-
tributed 𝛽-(1–4) linked D-glucosamine (deacetylated unit)
and N-acetyl-D-glucosamine (acetylated unit). It can be
derived from chitin found in crustacean shells, which is the
second most abundant biopolymer after cellulose [172].
Chitosan is able to form a gel by itself, without the need
of additives [173]. That may happen via hydrogen bonds,
hydrophobic interactions, and chitosan crystallites [174].
These hydrogels can also be formed by blending chitosanwith
other water-soluble nonionic polymers [175] or polyol salts
[176]. Since it is of polycationic nature in acidic conditions,
chitosan can also form hydrogels through interaction with
negatively charged molecules [177]. Another type of chitosan
hydrogels can be formed via covalent bonds with metal ions
[178], though these gels are less suitable for biomedical use
[173]. Finally, the gelation of chitosan could also be obtained
through covalent bonding between polymer chains. These
bonds make the hydrogel more stable because the gelation
is irreversible. Nevertheless, this approach may alter the
primary structure of chitosan, which will lead to changes in
its properties [173].
Chitosan hydrogels are pH-sensitive, being soluble in
dilute aqueous conditions and precipitating into a gel at
neutral pH [179]. The fact that this polymer is biodegradable
and biocompatible is also very important for being used as a
scaffold in tissue engineering applications. In vertebrates it is
mainly degraded by lysozyme and some bacterial enzymes in
the colon [180].
In what concerns neuronal repair, chitosan is commonly
applied in the production of tubular structures most fre-
quently used in peripheral nervous system [181]. However,
chitosan hydrogels have also been applied in neural tissue
engineering. For instance, the use of chitosan/glycerophos-
phate salt (GP) hydrogels showed that this type of gels
provides a suitable 3D scaffolding environment for neurons,
namely, fetal cortical mouse cells [179]. Addition of peptides,
like poly-D-lysine, also showed the capacity to improve
scaffold biocompatibility and nerve cell affinity for chitosan
materials [182].
3.2.6. Gellan-Gum. Finally, the recent use of gellan-gum-
(GG-) based hydrogels for CNS applications has already been
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shown to be promising. GG is a natural polysaccharide that
is produced by the bacterium Pseudomonas elodea [183]. Its
structure consists of repeating units of a tetrasaccharide,
composed by two residues of D-glucose, one residue of L-
rhamnose and another of D-glucuronic acid [D-Glc(𝛽1→
4)D-GlcA(𝛽1→ 4)D-Glc(𝛽1→ 4)L-Rha(𝛼1→ 3)]n [184].This
linear anionic polysaccharide exists in both the acetylated and
deacetylated forms, originating thermoreversible gels with
different mechanical properties according to the degree of
deacetylation [183].
GG is noncytotoxic and particularly resistant to heat
and acid stress, being useful in culture of extremophile
organisms [185]. The gelation process of this biomaterial is
ionotropic, meaning that the presence of cations is necessary
for the formation of a stable hydrogel structure [186]. In this
process, divalent cations promote a more efficient gelation
than monovalent cations [187], at the same time that several
structural changes take place. At higher temperatures, GG is
in a coil form. As temperature decreases, there is a thermore-
versible transition from coil to double-helix structures.These
structures form oriented bundles by self-assembly, which are
called junction zones. Untwined regions of polysaccharide
chains can also link with the junction zones, leading to the
formation of a three-dimensional network that assembles the
gel [187].
Regarding SCI applications, our group has developed
different strategies based on GG hydrogels [109, 131]. In
2010, Silva et al. [109] conjugated GGwith three-dimensional
tubular structures made of a biodegradable blend of starch
(SPCL). This construct was revealed to be noncytotoxic and
capable of supporting the in vitro culture of oligodendrocyte-
like cells. Moreover, when applied in vivo in a hemisection rat
SCI model, it was shown that the scaffold was well integrated
in the lesion site without eliciting any chronic inflammatory
processes [109]. In 2012, the same construct was adapted
to enhance osteointegration by premineralizing the external
surfaces of the SPCL structure [131]. By using a sodium silicate
gel as nucleating agent, it was possible to create two distinct
environments, one aimed at inducing osteogenic activity
(external surface) and another for fostering neuroregenera-
tion (internal surface) [131].
A common modification employed in this type of hydro-
gels is the addition of different peptide sequences that
mimic the ECM [151, 188], with the purpose of improving
phenomena like cell adhesion, growth, and development
[189]. In this sense, our group has modified GGwith GRGDS
fibronectin peptide, which resulted in the enhancement of
cell proliferation and metabolic activity, as will be described
in detail in the next section [130, 190].
3.3. Synthetic Hydrogels. Regarding synthetic hydrogels, their
biggest advantage is the fact that they can be tailored to fit the
needs for a certain application. From physical and chemical
properties to degradation rates, many aspects of their struc-
ture can be modulated in order to improve their biocompat-
ibility anddegradation rate [191].Thefindings relatedwith the
use of biodegradable poly(lactic acid) (PLA) and poly(lactic-
co-glycolic acid) (PLGA) hydrogels, methacrylate-based
hydrogels, and poly(ethylene glycol) (PEG) hydrogels will be
briefly discussed here.
3.3.1. Poly(lactic acid) (PLA) and Poly(lactic-co-glycolic acid)
(PLGA). PLGA/PLA polymers are members of the 𝛼-
hydroxy acid class of compounds and are composed of syn-
thetic biodegradable aliphatic polyesters [192]. For control-
ling the degradation rate and mechanical properties of these
polymers, it is possible to vary the ratio of monomer units
and their stereochemistry (either D- or L-form), as well as the
molecular weight distribution of their chains [193]. Since
PLGA and other similar polymers have been approved by the
FDA for use in the repair of human peripheral nerves, their
translation into CNS-related injuries seems promising [194].
In SCI applications, Patist et al. [138] tested the effects of
poly(D,L-lactic acid) macroporous guidance scaffolds (in the
form of foams), with or without BDNF, on a model of tran-
sected rat spinal cord. Foams were embedded in fibrin glue
containing acidic-FGF, resulting in some gliotic and inflam-
matory response in the cord-implant interfaces. In addition,
in BDNF-containing foams, 20% more NeuN-positive cells
(marker for neurons) were present in the spinal nervous
tissue in the rostral stump, as compared to controls, four
and eight weeks after implantation, respectively. These same
foams showed a significant higher level of vascularization.
Curiously, treatmentwith fibrin only yieldedmore axons than
the other groups. Through behavioral analysis, similar func-
tional improvements in all groups were found [138]. Further-
more, PLA microfibers, in an aligned or random form, were
implanted in rats subjected to a complete transection of the
spinal cord. Four weeks after injury, both types of microfibers
facilitated the infiltration of host tissue and allowed the
closure of the initial three millimeters gap. However, aligned
PLA fibers promoted longer distance of rostrocaudal axonal
regeneration as compared to random PLA fibers or film
controls [133].
Regarding PLGA, nano- andmicroparticles of this hydro-
gel have been widely used as delivery agents for tissue engi-
neering applications [195]. In a SCI animal model, Fan et al.
[135] used PLGA nerve conduits in combination with recom-
binant human NT-3 (rhNT-3). Rats were subjected to a
complete thoracic transection of the spinal cord and then
PLGA was implanted together with an rhNT-3 single dose
administration. Animals treated with the combinatorial
approach presented significantly improved performances in
the BBB2 (Basso, Beattie, and Bresnahan) rating locomotor
scale and grid walk tests [135].
3.3.2. Methacrylate-Based Hydrogels
Poly[N-2-(hydroxypropyl) methacrylamide] (PHPMA).
PHPMA hydrogels were first described by Woerly and col-
leagues [140, 141]. They synthesized a biocompatible and
heterogeneous hydrogel, with an open porous structure that
allowed the transport of both small and large molecules, as
well as the migration of cells and blood vessels [141]. This
hydrogel also presented viscoelastic properties similar to the
neural tissue [140]. When implanted into a transected rat
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spinal cord, the hydrogel successfully bridged the tissue defect
favoring cell growth, angiogenesis, and axonal growth within
the microstructure of the network [140]. This hydrogel was
showed to be permissive to the growth of a reparative tissue,
composed of glial cells, blood vessels, axons, and dendrites
and even ECM molecules, such as laminin and/or collagen
[141]. Other features of PHPMA hydrogels include a reduc-
tion of necrosis and cavitation in the adjacent white and
gray matter of transected rat spinal cords [139]. Furthermore,
using this type of hydrogels in cats subjected to a transec-
tion lesion provided some motor benefits, as compared to
nontreated cats [196]. More recently, PHPMA hydrogels were
used as a matrix in order to create an appropriate microen-
vironment for axonal regeneration in SCI rats. Hydrogel-
implanted animals exhibited an improved locomotor BBB2
score and an overall better coordination in neuromuscular
evaluations, such as breathing adjustment to electrically
evoked isometric contractions and H-reflex recovery. After
immunohistochemistry analysis, ED-1 positive cells accumu-
lation (macrophages/monocytes) was evident at the border
of the lesion. At the same time, a larger number of neuro-
filament-H positive axons penetrated the matrix. In addition,
there was also myelin preservation rostrally and caudally to
the lesion [197].
Poly(2-hydroxyethyl methacrylate and 2-hydroxyethyl metha-
crylate-co-methyl methacrylate) (PHEMA/PHEMA-MMA).
As other synthetic hydrogels, PHEMA/PHEMA-MMA poly-
mers have the disadvantage of being nonbiodegradable [107,
122].Nevertheless, this property allows them to remain stable,
even upon implantation [144]. In addition, these are bio-
compatible hydrogels, with the capacity of swelling in water
and retaining significant amounts of water without dissolving
[198].
PHEMA polymers are the most actively researched
nondegradable materials used for nerve guidance channels
[193], because they possess soft, tunable mechanical prop-
erties and can be easily molded into tubular shapes, with
controlled dimensions, morphology, and permeability [199].
Furthermore, since PHEMA synthesis is carried out at low
temperatures and without toxic solvents, it is possible to
incorporate bioactive compounds into the polymer scaffold
[107].
When applied in a rat transection model, PHEMA-
MMA hydrogel conduits allowed a continuity of tissue
within the synthetic guidance channels created [107]. These
conduits were further combined with different matrices and
growth factors, leading to increased axonal density within
the channels, as compared to unfilled channel controls [122].
Nevertheless, it was shown that the degree of integrity of the
conduits was drastically reduced 16 weeks after implantation,
when compared to eight weeks’ time point [200]. Moreover,
an important improvement was performed on PHEMA con-
duits by introducing coils into nerve channel’s walls in order
to provide reinforcement [201]. For instance, PHEMA-
MMA guidance channels containing poly-caprolactone coils
showed greater patency (openness) than nonreinforced chan-
nels, resulting in regeneration similar to autografts, regarding
peripheral nervous system injury [201]. PHEMA sponges
have also been used as a conductive substrate for regenerating
axons in rats subjected to a spinal cord contusion lesion.
These sponges were impregnated with collagen prior to
implantation into the dorsal funiculus after the lesion. Two
and four months after implantation, a minimal fibroglial
reaction was observed, associated with low accumulation of
mononuclear cells or angiogenesis within the sponge and
spinal cord interface.Moreover, the cystic cavity was virtually
absent and axons labeled with anterograde tracers penetrated
and elongated through the full length of the sponge [202].
Modified PHEMA-based hydrogels have also been used
in order to increase cellular adhesion [203]. For instance,
a hydrogel structure modification with laminin-derived
peptides—tyrosine-isoleucine-glycine-serine-arginine and
isoleucine-lysine-valine-alanine-valine (YIGSRand IKVAV)—
led to a significant increase of DRG cells survival, after two
days in culture, as compared to unmodified hydrogels [203].
Furthermore, implanted PHEMA hydrogels in a model of
partial cervical hemisection injury in rats have only induced
a modest cellular inflammatory response, which disappeared
after four weeks. In addition, minimal scarring was observed
around the matrix. A considerable level of angiogenesis
was observed within the hydrogels and, when soaked in
BDNF, axonal penetration into the gel was observed [204]. In
another model of complete transection of the cord, PHEMA
hydrogels were implanted either immediately or one week
after SCI.Threemonths later, histological evaluation revealed
that the hydrogel adhered well to the spinal cord tissue. In
addition, an ingrowth of connective tissue elements, blood
vessels, neurofilaments, and Schwann cells throughout the
gel was observed. Moreover, there was a significant reduction
in pseudocyst volume, which was more evident in animals
treated one week after injury [205]. More recently, Kubinova´
et al. used PHEMA hydrogels with oriented pores and
modified with SIKVAV peptide in a spinal cord hemisection
model. From three types of hydrogel tested (with different
elastic modulus and porosities), the best option promoted
tissue bridging and an aligned axonal ingrowth [206].
3.3.3. Poly(ethylene glycol) (PEG).Poly(ethylene glycol) (PEG)
is a nontoxic polyether compound that is water soluble and
known to resist protein adsorption and cell adhesion [207].
These properties make PEG polymer highly resistant to
recognition by the immune system after implantation [144].
Besides this, PEG helps to seal cell membranes after injury,
limiting cell death [144].
Depending on the cross-links created, PEG hydrogels can
be designed with varying degradation rates and can be used
as drug releasing vehicles [208, 209]. Moreover, they can be
additionally modified in order to increase cell adhesion [210,
211]. It is also known that PEG exhibits rapid clearance rates
and has already been approved for a wide range of biomedical
applications [208], including SCI.
In an in vivomodel of SCI, treatment with a PEG solution
by itself was capable of accelerating and enhancing the
membrane resealing process, restoring neuronal membrane
integrity. This led to suppressed levels of reactive oxygen
species (ROS) elevation and lipid peroxidation [136]. In a
similar approach, PEG treatment was also able to restore
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the conduction of compound action potential (CAP) in
injured spinal cords [137]. Furthermore, a study performed
on adult guinea pigs showed that, six hours after a spinal cord
contusion, a single subcutaneous injection of PEG (in saline)
produced a rapid recovery of SSEP propagation through the
lesion. This was followed by a significant recovery of the
cutaneous truncimuscle (CTM) reflex, which is a good index
of white matter integrity [212]. In another study, using dogs
as an animal model of SCI, PEG injection in the acute phase
was shown as clinically safe and induced a rapid recovery in
different outcome measures, as compared to conventionally
treated dogs [213]. Also, coupling PEG hydrogels with NT-3
and implanting these in a ratmodel of SCI provided improved
locomotor behavior to lesioned animals and greater axonal
growth, in comparison to controls treated with hydrogel
alone [214]. More recently, it was also shown that PEG was
effective even in conditions of low Ca2+ and low temperature
and that the hydrogel mechanism of action may be based on
a reduction of membrane tension, facilitating the resealing of
the membrane [215].
In conclusion, it seems that PEG action has two main
pathways: one is based on the protection against membrane
damage, which leads to reduced necrosis and apoptosis, while
the other is preventing the effects of mitochondria-derived
oxidative stress, showing a reduction in ROS formation and
lipid peroxidation [216].
3.4. Self-Assembly Peptides. Another alternative that has been
used in SCI research is the application of self-assembling
peptides (SAPs) [217]. These SAPs originate solid scaffolds
that are formed by self-assembly of peptide amphiphiles
from aqueous solutions [217]. The peptide sequences can
be customized for obtaining a specific cell response. When
cell suspensions are added to these aqueous solutions, the
amphiphilic molecules aggregate forming different nanofiber
networks. This aggregation happens mainly due to (1) the
presence of electrostatic repulsions between the negatively
charged SAPs and the cations present in culture media; and
(2) the partial hydrophobic nature of the SAPs. An injection
of liquid SAPs into living tissues will also lead to scaffold
formation [217]. The presence of a peptide of interest in
the hydrophilic part of the SAPs allows a significant motif
presentation to cells. Based on this concept, in 2004, Silva
and coworkers developed a SAP with IKVAV laminin motifs
[217]. Neural progenitor cells (NPCs) were encapsulated in
these gel-like scaffolds and remained viable for at least 22
days. Furthermore, this system was able to promote NPCs
migration and direct their differentiation largely into neu-
rons, while suppressing astrocyte differentiation [217]. This
was proved to be due to IKVAV presence, since a similar
SAP designed with the nonbioactive EQS (glutamic acid,
glutamine, and serine) peptide did not induce cell migra-
tion, sprouting of neurites, or neuronal differentiation [217].
Suppressing astrocyte differentiation and proliferation is
important since it can be associated with prevention of glial
scar formation [217]. Finally, neurons within these networks
were larger and produced longer neurites compared to
neurons grown in control cultures. Later in 2008, a work
published by the same group assessed the effects of SAPs with
IKVAV motifs in a mouse compression model of SCI [218].
Twenty-four hours after injury, SCI mice were treated with a
single injection of the IKVAV peptide amphiphiles (IKVAV-
PA) and the respective controls. First, IKVAV-PA was found
to be stable, being only biodegraded after 4 weeks. Then, the
in vivo application of these peptide amphiphiles to SCI mice
reduced the progression of astrogliosis (assessed after 5 and
11 weeks) and cell death (less apoptotic cells after 10 days).
At the same time, there was an increased number of oligo-
dendroglia at the site of injury, as compared to controls. The
IKVAV-PA also promoted the regeneration of both descend-
ing motor and ascending sensory fibers through the lesion
site 11 weeks following injury, even though fibers grew in a
random manner. In addition, mice treated with IKVAV-PA
presented a significant behavioral improvement as assessed
by the BBB2 locomotor scale [218]. An injection of the IKVAV
peptide alone did not induce functional recovery, which
reinforces the idea that the combination of SAPs and IKVAV
peptide is essential to produce an effect. In another study of
the same authors [219], an injection of IKVAV-PA provided
functional improvements both in mice and rats and in
two different models of SCI (compression and contusion,
resp.). Moreover, the IKVAV-PA treated animals presented a
significantly higher density of serotonergic fibers, caudal to
the injury site. Interestingly, this difference only appeared in
the chronically injured cord [219].The improved serotonergic
innervation may partially explain the functional improve-
ments observed in other studies [219].
More recently, Berns et al. [220] used a similar strategy by
modifying these aligned scaffolds with IKVAV or RGDS epi-
topes.These ECM-derived bioactive peptides were presented
on the surface of aligned nanofibers of the monodomain gel.
The growth of neurites from neurons encapsulated within
the scaffolds was enhanced, while the alignment guided the
neurites along the direction of the nanofibers [220].This fiber
alignment proved to be a powerful directional cue for neurite
outgrowth [220]. In addition, neurons cultured in the scaffold
for two weeks presented spontaneous electrical activity and
established synaptic connections [220]. Finally, when applied
in vivo, the scaffolds were able to form in situ within the
spinal cord and promoted the growth of oriented processes
[220]. In summary, this particular scaffold has the potential
to propagate electrical signals and neurite outgrowth in a
desired direction [220].
Using a different SAP, firstly introduced by Dong et al.
[221], Liu et al. tested the effects of a multidomain peptide
[glutamine, leucine, and lysine—K
2
(QL)
6
K
2
or (QL6)] on a
rat SCI compressionmodel [222]. QL6 was injected 24 h after
injury and led to a significant reduction in posttraumatic
apoptosis, inflammation, and astrogliosis. In addition, it pro-
moted tissue preservation and axonal regeneration. SCI rats
treated with QL6 also presented significant motor recovery,
as assessed by the BBB2 test [222].
Another interesting fact about SAPs is that, by modulat-
ing their mechanical properties, particularly their stiffness,
it is possible to influence neuronal differentiation and mat-
uration [223]. In line with this, Sur et al. [223] studied the
morphological development of hippocampal neurons when
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using SAPs with different fiber rigidities. Softer nanofiber
substrates provided an accelerated development of neuronal
polarity and the weaker adhesion of neurites to soft PA
facilitates easier retraction, which fosters the frequency of
“extension-retraction” events [223].
According to the reported findings, hydrogels may have
a high therapeutic value for SCI treatment. Therefore, their
future application for cell and/or drug delivery appears to be
promising. In addition, considering the previously reported
limitations often found within cellular based therapies, the
combination with biomaterials has been widely considered
as an alternative method to mediate cellular transplantation
more effectively.
4. Combining Biomaterials and Cell
Transplantation for SCI Treatment
In spite of the experimental groundwork regarding cell trans-
plantation and biomaterial-based therapies for SCI, their use
as single approaches presents some limitations. Regarding
biomaterials alone, it is not always easy to modulate their
properties so they respond exactly as expected. Moreover,
they are not able to replace the cells lost during SCI. On
the other hand, cell transplantation by itself is not capable of
recreating spinal cord complex architecture and stability, or
even direct axonal regrowth [11]. Hence, taking advantage of
what both therapies offer to overcome the multiple hurdles of
SCI, synergistic effects on regeneration and functional recov-
ery of the injured spinal cord can be provided if combined
strategies are employed [11, 14] (Figure 2).
In this sense, researchers have been focusing on the
use of biomaterials, specifically hydrogels, as systems for
cell encapsulation and delivery into injured spinal cords. As
summarized in Table 1, the advantages of these combinatorial
approaches have been revealed in several studies.
Regarding NSCs, artificial scaffolds made of synthetic
poly(glycolic acid) (PGA), PLA, and their copolymers have
been shown to be promising as cell carriers [224, 225]. How-
ever, the NSCs behavior was found to be dependent on the
mechanical characteristics of the scaffold, as the rate of NSCs
differentiation was higher in PLA nanofibers comparing to
microfibers, independently of the alignment [225]. Further-
more, the transplantation of NSCs with PLGA scaffolds into
SCI rats has been shown to maintain cell viability for longer
periods of time and improve the functional recovery of the
rats [226, 227]. In another interesting study, NSCs and
endothelial cells (ECs) were codelivered in a two-component
biomaterial composed of an outer PLGA scaffold and an
inner poly(ethylene glycol)/poly-L-lysine (PEG/PLL) macro-
porous hydrogel to the injured rat spinal cord in a hemisec-
tionmodel of SCI.The role of ECs in this approachwas to pro-
mote the vascularization of the scaffold in order to increase
NSCs survival. In effect, the number of functional blood ves-
sels at the lesion site has increased, though NSCs survival has
not, compared to the implant carrying only cells [228]. The
advantages of natural gels as a biomaterial to modulate NSCs
were also revealed in several studies. For instance, alginate
sponges contributed to the survival and differentiation of rat
hippocampus-derived neurosphere cells, after transplanta-
tion into injured rat spinal cords [229]. Following a similar
line, fibrin based hydrogels supported neurite outgrowth
[230]. In vivo they have also been shown to increase the
number of neural fibers in a subacute rat model of SCI,
delaying simultaneously the accumulation of GFAP positive
reactive astrocytes around the lesion [231]. More recently,
NSCs expressing GFP were embedded into growth-factor
cocktail-containing fibrin matrices and were found to differ-
entiate into neurons that were able to form synapses with the
host cells. Moreover, specific signaling pathways were found
to influence large axonal extension along the injury site.
Animals’ functional recovery was also observed [22]. After
chitosan/chitin films were shown to promote cell survival
in vitro [232], chitosan-based channels coated with laminin
were shown to significantly improve spinal cord-derived
NSCs survival, twelve weeks after transplantation in the
injured rat spinal cord. Still, axonal regeneration as well as
functional recovery was not promoted [233]. Finally, GG
hydrogels were also used to engraft NSCs in an in vitro study
performed by Silva et al. [130]. To enhance cell adhesion,
GG hydrogels were modified with GRGDS peptide using
Diels-Alder click chemistry. NSCs were found to adhere
and proliferate within the modified gels, when compared to
unmodified ones. In addition, OECs were used to further
enhance NSCs survival and outgrowth in this system. In the
cocultures, NSCs presented significantly greater survival and
proliferation compared to monocultures of NSCs [130].
MSCs combinationwith biomaterials has also emerged as
a potential tissue engineering approach, aiming at increasing
both MSCs engraftment efficiency and survival at the injury
site. For instance, therapeutic BM-MSCs in a poly(D,L-
lactide-co-glycolide)/small intestinal submucosa (PLGA/SIS)
scaffold induced nerve regeneration in a complete spinal
cord transection model [234]. Different defect lengths were
studied, with BM-MSCs survival being observed in general.
In addition, axonal regeneration as well as functional recov-
ery was also reported, though it was found to be depend-
ent on the defect length—smaller defects allowed for higher
functional recovery and regeneration [234]. Spinal cord
regeneration has also been extensively studied regarding the
implantation of MSC-containing macroporous hydrogels
based on derivatives of 2-hydroxyethyl methacrylate
(HEMA), 2-hydroxypropyl methacrylamide (HPMA), or
copolymers of HPMA [235] into spinal cord injuries. These
hydrogels were either modified by copolymerization with
a hydrolytically degradable crosslinker (N,O-dimethacryl-
oylhydroxylamine) or by different surface electric charges
(HEMA-sodium methacrylate (MA) negative charge;
HEMA-2[2-(methacryloyloxy)ethyl]trimethylammonium
chloride (MOETACl) positive charge). After implantation,
the hydrogels integrated well in the injury site and promoted
cellular ingrowth, more pronounced in the positively
charged HEMA/MOETACl hydrogels. Axons were found
to invade all the implanted hydrogels from both proximal
and distal stumps. Moreover, the hydrogels were resorbed by
macrophages and replaced by newly formed tissue contain-
ing connective tissue elements, blood vessels, astrocytic
processes, and neurofilaments. P(HEMA) and HPMA
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Figure 2:Theuse of hydrogelmatrices or their combinationwith cell therapy, such asMSC transplantation, for SCI treatmentmight potentiate
axonal regeneration and outgrowth through the injury site.
hydrogels were also modified with laminin-derived Ac-
CGGASIKVAVS-OH peptide sequences [236] and RGD
amino acid sequences [237], respectively. These significantly
increased the number of attached cells and their growth area
[236] and allowed the hydrogels to successfully bridge the
spinal cord cavity, while promoting axons infiltration within
it, as well as blood vessels and astrocytes growth [238].
Agarose, alginate, and matrigel are other natural hydro-
gels used for MSCs transplantation. Template agarose scaf-
folds were grafted with BM-MSCs expressing either NT-3
[121] or brain-derived neurotrophic factor (BDNF) [150] and
placed into spinal cord lesion site. Long-tract sensory axonal
regenerationwith increased linear organizationwas observed
into the spinal cord, even into severe, complete spinal cord
transection sites [150]. However, the formation of a host
reactive cell layer in the interface of the scaffold prevented
axonal penetration [121]. Regarding alginate and matrigel,
an in vitro study has reported the potential of these gels
in promoting DRG axonal regeneration when grafted with
different cell types, including BM-MSCs [239]. The incorpo-
ration of fibronectin in alginate was also considered. While
alginate alone inhibited both cell proliferation and DRG
neurite outgrowth, which was attenuated by the addition
of fibronectin or BM-MSCs, matrigel stimulated both cell
proliferation and DRG neurite outgrowth, in either the
absence or presence of cells. Fibrin has also been used to
transplant GFP-positive BM-MSCs into the cavity formed
after a hemisection spinal cord injury model in the rat. Four
weeks after transplantation, increased cell survival as well as
migration throughout the hydrogel was observed, accompa-
nied by functional improvement of the animal, in comparison
to animals that received just BM-MSCs or a vehicle control of
PBS [240]. More recently, GG was also suggested for MSCs
encapsulation [190]. The engraftment of BM-MSCs within
a GG hydrogel modified with GRGDS fibronectin-derived
peptide as previously described [130] increased cell prolifera-
tion and metabolic activity, when compared to unmodified
hydrogels. Moreover, BM-MSCs secretome was positively
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Table 1: Therapeutic potential of combinatorial approaches based on cell therapy and biomaterials for SCI treatment.
Cells Biomaterial In vitroimprovements
In vivo
ReferencesFunctional
improvements
Histological
improvements
NSCs
PLA ✓ — — [225]
PLGA — ✓ ✓ [226, 227]
Alginate — ✓ ✓ [229]
Fibrin ✓ ✓ ✓ [230, 231]
Chitosan ✓ ✓ M [232, 233]
Gellan-gum ✓ — — [130]
NSCs plus ECs PLGA-PEG/PLL — M ✓ [228]
NSCs plus OECs Gellan-gum/GRGDS ✓ — — [130]
MSCs
PLGA/SIS — ✓ ✓ [234]
HEMA, HPMA, and HPMA copolymers — ✓ ✓ [235, 236, 238]
Agarose — M ✓ [121, 150]
Alginate ✓ — — [239]
Alginate/fibronectin ✓ — — [239]
Matrigel ✓ — — [239]
Fibrin — ✓ ✓ [240]
Gellan-gum/GRGDS ✓ — — [190]
OECs
SAP-IKVAV ✓ — — [243]
PHB-b-DEG ✓ — — [244]
Alginate M — — [239]
Alginate/fibronectin ✓ — — [239]
Matrigel ✓ — — [239]
OECs plus MSCs Serum-derived albumin — ✓ ✓ [245]
SCs
PHB M M ✓ [249]
PAN/PVC — M ✓ [129]
Alginate ✓ — — [239]
Laminin/collagen — ✓ ✓ [247]
SCs plus OECs PAN/PVC plus chABC delivery — ✓ ✓ [250]
PLLA-PLLA oligomers — M ✓ [251]
BM-MSC-SCs Matrigel ✓ ✓ ✓ [246, 252]
✓: improvements observed; M: no improvements observed; —: not studied.
influenced, as proven by the enhancement of the survival and
differentiation of primary cultures of hippocampal neurons
in vitro [190].
Taking into account the well known capacity of OECs
to support and guide axonal elongation [89] and also their
interesting results when transplanted into SCI lesion models
[241, 242], their combination with a 3D matrix also holds
great promise regarding SCI repair. Among the various
studies exploring the combination of biomaterials and OECs,
Novikova et al. [239] used an in vitro model to test OECs
biocompatibility (among other cells) with different hydrogels.
In alginate hydrogels, OECs presented an atypical spherical
shape and their metabolic activity was inhibited. However,
when alginate was complemented with fibronectin, OECs
were the only cells able to proliferate. When OECs were
cultured in matrigel, their proliferation was stimulated and
their typical morphology was preserved [155]. Another in
vitro study explored the biocompatibility of IKVAV self-
assembling peptide nanofiber scaffold hydrogels using OECs.
Either on 2D or on 3D surfaces, OECs could survive and
migrate in the scaffolds. In addition, cell number, viability,
andmorphology were not significantly different compared to
OECs cultured with poly-L-lysine [243]. More recently, Chan
et al. [244] tested OECs ability to grow on polyhydrox-
ybutyrate-polyethylene glycol hybrid polymers (PHB-b-
DEG). OECs proliferation was enhanced when cultured in
PHB-b-DEG films. Moreover, no cytotoxic responses were
observed, and cell viability was maintained. Finally, it was
also shown that OECs grown in PHB-b-DEG films entered
into the DNA replication (S) phase and mitotic (G2-M)
phase during the cell growth cycle, being associated with
low apoptosis [244]. Moving to in vivo experiments, Ferrero-
Gutierrez et al. [245] assessed the locomotor recovery of SCI
rats when treated with a serum-derived albumin scaffold
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seeded with both OECs and ASCs. First, it was shown that
both cell types adhered to the scaffold, remained viable, and
expressed specific markers. Then, rats treated with the cell-
seeded scaffolds showed improved locomotor skills at differ-
ent time points, when compared to untreated SCI animals.
Furthermore, there was a reduction in glial scar formation
and the presence of cells expressing markers of neurons and
axons at the injury site was observed [245].
Finally, the use of biomaterials for SCs encapsulation
has also been considered. Although these cells belong to the
peripheral nervous system, SCs application in a SCI context is
quite common [246, 247]. This is mainly due to SCs myeli-
nating capacity [248]. Therefore, the conjugation of SCs with
biomaterials-based strategies seems an obvious step towards
SCI regeneration. In a work developed by Novikova et al.
[239], SCs presented an atypical shape and an inhibited
metabolic activity when they were cultured on alginate
hydrogels. However, the combination of both attenuated
alginate inhibitory effects over DRG neurites outgrowth. In
addition, SCs proliferation was stimulated when cultured on
matrigel [155]. In another work from the same authors, SCs
were cultured on biodegradable tubular conduits made from
poly-beta-hydroxybutyrate (PHB) [249]. Then, the scaffold
was implanted in SCI rats and the presence of SCs allowed the
infiltration of neurofilament-positive axons within the con-
duits, associated with numerous raphaespinal and calcitonin
gene related peptide- (CGRP-) positive axons.Therefore, this
conjugate seems to support axonal regeneration after SCI
[249]. In fact, the association of SCs with guidance structures
has been recurrent in SCI experimental approaches [129,
250]. For instance, Bamber et al. [129] tested a SCI graft,
where cells were seeded on mini-guidance channels com-
posed of 60 : 40 polyacrylonitrile : polyvinylchloride copoly-
mer (PAN/PVC).This construct, associated with the delivery
of neurotrophins, promoted axonal outgrowth from themini-
channels into the distal host spinal cord [129]. An identical
approach was performed by Fouad et al. [250], where SCs
were grafted in 60 : 40 PAN/PVC channels and transplanted
into the site of injury of SCI rats. This was complemented
with chABC delivery and OECs transplants. This combined
therapy provided significant improvements in the BBB2
locomotor score, which was correlated with an increased
number of myelinated axons in the SCs bridge [250]. Tubular
scaffolds made of high-molecular-weight poly(L-lactic acid)
(PLLA) mixed with 10% PLLA oligomers were also used
to seed SCs and implanted on rats subjected to a complete
transection of the spinal cord [251]. This construct was able
to hold without collapsing four months after injury. Through
several time points analyzed, SCs remained present in the
tubes, which were quite vascularized. In addition, there were
a significant number of myelinated axons. However, after
two months the growth and myelination presented a slight
decrease [251]. In another interesting approach, Kamada et al.
[252] differentiated BM-MSCs into SCs in vitro. Then, BM-
MSC-derived SCs (BM-MSC-SCs) together with matrigel
were used to fill an ultra-filtration membrane tube. This
construct was grafted into the gap of completely transected
spinal cords of adult rats. In these animals, the number of
neurofilament- and tyrosine hydroxylase- (TH-) immunore-
active nerve fibers was significantly higher when compared
to control groups. In addition, the same animals showed a
significant recovery of the hindlimb function [246]. More
recently, the same group combined BM-MSC-SCs with
matrigel.This mixture was injected into the lesion site, 9 days
after a contusion lesion in adult rats.The results demonstrated
that, in comparison to control groups, BM-MSC-SCs with
matrigel-treated animals presented a smaller cystic cavity
area, a higher number of growth associated protein-43
(GAP43) positive fibers, a larger number of TH- or serotonin-
positive fibers at the lesion epicenter and at a caudal level, the
formation of peripheral-typemyelin near the lesion epicenter,
and a significant recovery of hind limb function [246].
In a contusion injury model, Patel et al. [247] implanted
SCs with in situ gelling laminin/collagen matrices. In com-
parison to cell transplantation by itself, the 3D matrices
enhanced long-term cell survival, but not proliferation. In
addition, graft vascularization was improved and the degree
of axonal ingrowth was also increased. Finally, some level of
functional recovery was also achieved, as assessed through
the BBB2 locomotor score [247].
These are very promising results regarding the use of
biomaterials as cell carriers for SCI treatment. In the future,
the challengewill be to define themost promising biomaterial
to engineer and design effective cell-based therapies.
5. Conclusions
The inability of the adult CNS to regenerate is not completely
understood regarding the mechanisms that are responsible
for repressing axonal regeneration and spinal cord functional
recovery. However, extensive progress has been made in
neural regeneration in SCI. Therefore, we herein focused
on some the most promising therapies currently used for
SCI repair: cell- and biomaterial-based therapies and their
conjugation.
Accomplishing axonal regeneration and reconnection
across the lesion is the major goal for SCI repair [2]. Clearly,
the use of cell transplantation is one of the top promising
strategies for this kind of treatment. Their translation to
human clinical applications is currently ongoing, with issues
regarding cell biosafety and biocompatibility being exten-
sively tested. Nevertheless, the efficacy of cell therapy is still
compromised by the innumerous barriers presented by SCI,
including significant cell death observed following trans-
plantation, which clearly decreases the effectiveness of this
technique. Besides, in chronic SCI, cell transplantation is
not sufficient to promote tissue remodeling and axonal
regeneration across the dense glial scar. Thus, regenerative
strategies using scaffolds to bridge the two segments of the
injured spinal cord and provide a three-dimensional environ-
ment for the regenerating axons are very attractive. In line
with this, the advantages of using biomaterials that support
cell transplantation were highlighted. However, the evolution
of sophisticated 3D scaffolds from 2D conditions for such
microenvironment of SCI is not free of challenges [193]. From
requirements such as oxygen availability and nutrients diffu-
sion for the encapsulated cells, to the variability on gradients
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and defects that result in heterogeneities in the synthetic
microenvironment, there are many aspects that must be
considered for the culture of mammalian cells in 3D envi-
ronments, since it is already established that cell survival and
differentiation and tissue homeostasis are highly dependent
on these conditions [253].
Nevertheless, with increasing knowledge on the mech-
anisms by which specifically designed biomaterials support
cell behavior, and thus how CNS regeneration is promoted,
the future of SCI regeneration is probably linked to combina-
torial approaches, integrating the multiple stimuli from these
two elements. Meanwhile, advanced studies on how biomate-
rials modulate cellular activity and the biosafety and efficacy
of this therapy must be addressed, in view of its clinical
application. In this way, medicine and tissue engineering
must work together in order to create better therapies.
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